We are live on ! Find out more
TCON

TRACON Pharmaceuticals, Inc. Common Stock
TCON

Delisted

TCON was delisted on the 27th of June, 2024.

Back to rankings

29 hedge funds and large institutions have $1.39M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

54% more capital invested

Capital invested by funds: $903K → $1.39M (+$487K)

21% more funds holding

Funds holding: 24 → 29 (+5)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
29
Holders Change
+5
Holders Change %
+20.83%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
2
Reduced
5
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$108K
2
Renaissance Technologies
Renaissance Technologies
New York
+$48.3K
3
Jane Street
Jane Street
New York
+$43.5K
4
UBS Group
UBS Group
Switzerland
+$21.8K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$18.6K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$484K
2
BFM
Boothbay Fund Management
New York
-$45.3K
3
Millennium Management
Millennium Management
New York
-$27.9K
4
Squarepoint
Squarepoint
New York
-$5.56K
5
GS
GTS Securities
New York
-$2.76K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
1
LPL Financial
California
$194K +$108K +22,533 New
Acadian Asset Management
2
Acadian Asset Management
Massachusetts
$176K – – –
Squarepoint
3
Squarepoint
New York
$167K -$5.56K -1,165 -6%
Renaissance Technologies
4
Renaissance Technologies
New York
$129K +$48.3K +10,110 +206%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$123K +$18.6K +3,896 +37%
Vanguard Group
6
Vanguard Group
Pennsylvania
$113K – – –
BlackRock
7
BlackRock
New York
$112K -$282 -59 -0.5%
Jane Street
8
Jane Street
New York
$78.4K +$43.5K +9,115 New
UBS Group
9
UBS Group
Switzerland
$39.3K +$21.8K +4,567 New
JJ
10
Johnson & Johnson
New Jersey
$36.1K – – –
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$33.5K +$18.6K +3,893 New
State Street
12
State Street
Massachusetts
$32.3K – – –
Millennium Management
13
Millennium Management
New York
$32.1K -$27.9K -5,840 -61%
Corient Private Wealth
14
Corient Private Wealth
Florida
$24.7K – – –
HF
15
HRT Financial
New York
$23K +$13K +2,718 New
Two Sigma Investments
16
Two Sigma Investments
New York
$15K +$8.31K +1,741 New
XT
17
XTX Topco
Cayman Islands
$12K +$6.68K +1,398 New
EPP
18
ETF Portfolio Partners
Kansas
$10.6K +$5.88K +1,232 New
Northern Trust
19
Northern Trust
Illinois
$9.32K – – –
SA
20
SpiderRock Advisors
Delaware
$8.3K +$5.49K +1,149 New
H
21
HoyleCohen
California
$5.59K – – –
JF
22
Jump Financial
Illinois
$4.51K +$2.51K +525 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$4.41K – – –
Mercer Global Advisors
24
Mercer Global Advisors
Colorado
$4K +$2.39K +500 New
TRCT
25
Tower Research Capital (TRC)
New York
$3.26K -$664 -139 -27%
1
2

TCON Hedge Fund Activity: Q1 2024 in Review

29 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2024, worth a combined $1.39M — up 54% from $903K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TCON positions and 6 closed out — a net gain of 5 holders — while 2 added to existing stakes and 5 trimmed.

The largest buyer was LPL Financial, opening a new position worth an estimated $108K. The largest seller was Ikarian Capital, exiting entirely with an estimated $484K sold.

  • 29 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2024, up from 24 in Q4 2023.
  • Funds reported $1.39M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2024, up 54% quarter-over-quarter.
  • 11 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 6 closed out, a net change of +5 holders.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was LPL Financial, an estimated $108K added.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Ikarian Capital, an estimated $484K sold.

Based on aggregated 13F filings for Q1 2024.